Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Data show that the cancer vaccine Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival in ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

NRG Oncology recently reported the results of the National Cancer Institute sponsored phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) ...

A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test ...